162 related articles for article (PubMed ID: 27345620)
1. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
2. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
3. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
5. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
6. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
Huang Y; Su MW; Jiang X; Zhou Y
Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
[TBL] [Abstract][Full Text] [Related]
7. miRNA‑135a regulates Hut78 cell proliferation via the GATA‑3/TOX signaling pathway.
Wei H; Liu R; Guo X; Zhou Y; Sun B; Wang J
Mol Med Rep; 2019 Mar; 19(3):2361-2367. PubMed ID: 30747224
[TBL] [Abstract][Full Text] [Related]
8. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
9. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
10. TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.
Ahmed MM; Hegazy AA; Embaby A; Nawwar EM; Hegazy SA; Ibrahim HM; Gobran MA
Turk Patoloji Derg; 2023; 39(1):15-22. PubMed ID: 35642346
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
12. TOX Expression in Mycosis Fungoides and Sezary Syndrome.
Pileri A; Cavicchi M; Bertuzzi C; Righi S; Zengarini C; Sabattini E; Roncador G; Agostinelli C
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885488
[TBL] [Abstract][Full Text] [Related]
13. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
[TBL] [Abstract][Full Text] [Related]
14. Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study.
Geller S; Gomez CJ; Myskowski PL; Pulitzer M
J Am Acad Dermatol; 2019 Jun; 80(6):1704-1711. PubMed ID: 30716405
[TBL] [Abstract][Full Text] [Related]
15. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients.
Wechsler J; Ingen-Housz-Oro S; Deschamps L; Brunet-Possenti F; Deschamps J; Delfau MH; Calderaro J; Ortonne N
Pathology; 2022 Oct; 54(6):729-737. PubMed ID: 35577607
[TBL] [Abstract][Full Text] [Related]
18. TOX acts an oncological role in mycosis fungoides.
Yu X; Luo Y; Liu J; Liu Y; Sun Q
PLoS One; 2015; 10(3):e0117479. PubMed ID: 25811617
[TBL] [Abstract][Full Text] [Related]
19. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
20. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
